study reveals that SGLT2 inhibitors consistently lower the risk of major adverse cardiovascular events by 9% across various patient groups, especially impacting cardiovascular death reduction, highlighting their broad therapeutic potential beyond diabetes management.
SGLT2 inhibitors: A game-changer in preventing heart failure and sudden cardiac deaths
- Post author:
- Post published:April 9, 2024
- Post category:uncategorized